Abstract

Streptomyces sp., belonging to Gram-positive bacteria, is well-known as a factory producing secondary metabolites that play a vital role in the pharmaceutical industry. Compounds derived from
Streptomyces sp. exhibit a wide range of biological activities, such as antioxidant, antibacterial,
antiviral, immunosuppressive, and especially anticancer properties. Many important anticancer
agents that originated from Streptomyces sp. have made significant contributions to the medical
field, including actinomycin D, mitomycin D, bleomycin, doxorubicin, and streptozotocin. Therefore, in the quest for new bioactive compounds, Streptomycessp. strains have attracted great interest from scientists, among which endophytic Streptomycessp. from medicinal plants are emerging
as a promising source for isolation. The ethyl acetate extract of the culture medium of Streptomyces
sp. SS7, isolated from the medicinal plant Crinum latifolium, was investigated for its anticancer potential on the A549 lung cancer cell line using the MTT assay. The results showed that the IC50 values
of this cell line at 48 h and 72 h were 645.65 ± 1.88 µg/mL and 767.36 ± 1.04 µg/mL, respectively.
Furthermore, the SS7-EA extract inhibited A549 cell migration by 4.29 times in the wound-healing
assay. These observations lay the groundwork for further research on the Streptomyces sp. SS7
strain, aiming to identify and isolate bioactive secondary metabolites with potential applications
supporting cancer treatment